ME Therapeutics Holdings Inc.
METX
CNSX
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Net Income | -51.83% | -15.88% | -8.25% | 30.93% | -30.81% |
| Total Depreciation and Amortization | 44.76% | 150.00% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -91.45% | -98.50% | -98.32% | -98.93% | 108.22% |
| Change in Net Operating Assets | -77.46% | 127.78% | 804.55% | 25.66% | -235.16% |
| Cash from Operations | -73.69% | -118.73% | -62.99% | -79.31% | -95.94% |
| Capital Expenditure | 79.83% | 81.25% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 79.83% | 91.61% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.45% | -207.41% | -- | -- | 59.25% |
| Issuance of Common Stock | -100.00% | -- | -- | -100.00% | -4.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -101.69% | 3,097.50% | -116.36% | -103.51% | -8.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -160.75% | 9.27% | -93.75% | -209.54% | -34.64% |